Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the $H^+/K^+$-ATPase enzyme system in the gastric parietal cell. It is available in oral (delayed-release tablets, granules) and intravenous (IV) formulations.
## Primary Indications
* Short-term treatment of erosive esophagitis associated with GERD.
* Maintenance of healing of erosive esophagitis.
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome).
* Prophylaxis of stress ulcers (IV use in critical care).
## Adult Dosing
* **GERD/Erosive Esophagitis:** 40 mg PO daily for 8 weeks; may repeat for another 8 weeks.
* **Maintenance of Healing:** 40 mg PO daily.
* **Hypersecretory Conditions:** 40 mg PO BID, adjusted based on patient need (doses up to 240 mg/day used).
* **Stress Ulcer Prophylaxis (IV):** 40 mg IV daily or BID.
## Pediatric Dosing
* **GERD (5 years and older):**
* 15 kg to <40 kg: 20 mg PO daily.
* ≥40 kg: 40 mg PO daily.
* **Safety/Efficacy:** Not established for children <5 years for GERD. Use in infants/neonates for stress ulcer prophylaxis is off-label and varies by intensive care unit protocols.
## Dose Adjustments
* **Hepatic Impairment:** Reduce frequency; clinical practice often suggests 40 mg every other day or 20 mg daily in severe cirrhosis.
* **Renal Impairment:** No dosage adjustment necessary.
## Contraindications
* Known hypersensitivity to pantoprazole or substituted benzimidazoles.
* Concomitant use with rilpivirine-containing products.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, flatulence.
* **Serious:** *Clostridioides difficile*-associated diarrhea, hypomagnesemia, vitamin B12 deficiency (long-term use), acute interstitial nephritis, cutaneous/systemic lupus erythematosus, and increased risk of bone fractures.
## Key Drug Interactions
* **pH-Dependent Drugs:** May decrease absorption of ketoconazole, atazanavir, and mycophenolate mofetil.
* **Methotrexate:** May increase methotrexate serum levels (risk of toxicity).
* **Warfarin:** Potential for increased INR/PT; monitor closely.
## Monitoring
* **Long-term use:** Monitor magnesium levels and vitamin B12 status.
* **Symptomatic:** Evaluate for resolution of reflux symptoms; assess need for de-escalation or discontinuation to prevent long-term safety risks.
* **Renal:** Monitor for signs of interstitial nephritis (rare).
## Clinical Pearls
* **Administration:** Tablets can be taken without regard to food, but typically recommended 30-60 minutes before a meal for optimal PPI efficacy. Tablets must be swallowed whole.
* **IV Administration:** IV pantoprazole should be transitioned to oral as soon as the patient can tolerate it. IV bolus should be administered over 2–15 minutes depending on the institution's medication safety policy.
* **"Deprescribing":** Periodically evaluate if the PPI is truly indicated. Chronic PPI use is associated with polypharmacy and potential dependency/rebound acid hypersecretion upon withdrawal.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice guidelines vary by institution and patient-specific factors. Always verify the most current prescribing information via official FDA labels, hospital-specific formularies, or clinical decision support tools (e.g., Lexicomp, UpToDate) before prescribing or administering medication.
